About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI | Clinical Trials | Clareo Health

Back to clinical trial search

RECRUITINGPhase 2NCT05305911

Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI

The purpose of the research is to determine whether a class of medication called SGLT2 inhibitor will improve the heart's function and reduce its enlargement after a heart attack. Participation in thi...

Lead sponsor: Minneapolis Heart Institute Foundation•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Sarah Schwager, RN

CONTACT

612-863-3833 [email protected]

Sponsors

Lead Sponsor

Minneapolis Heart Institute Foundation

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Patients with their first STEMI (\>18 years) who underwent successful primary PCI and able to give informed consent
•At least mild LV dysfunction (LVEF \< 50%) on echocardiogram, cMRI or Left Ventriculargram following PCI
•Infarct size that is \> 10% of LV mass
•The presence of MVO that is \> 10% of infarct size

Exclusion Criteria

•Contraindication to cardiac MRI
•Life expectancy \< 1 year
•Previous CABG or Valve Surgery
•Previous STEMI
•Pregnant or planning to become pregnant or lactating women
•Cardiogenic shock (not resolved)
•Atrial fibrillation or recurrent sustained ventricular arrhythmias (excluding PVCs)
•GFR\<30 ml/min/1.73m2 or end-stage renal disease on dialysis
•Type 1 diabetes mellitus or history of diabetic ketoacidosis
•Type I or II diabetes with insulin use
•Prior intolerance of SGLT2 inhibitors
•Current use of SGLT2 inhibitors (randomized patients only)
•Contraindications to gadolinium

Related studies

Immunomodulatory Effects of PCSK9 Inhibition

NCT05720156 · Atherosclerotic Cardiovascular Disease, Cardiovascular Diseases, and more

Home Telemonitoring In Patients After Myocardial Infarction

NCT04664881 · Myocardial Infarction, Heart Attack

Not Yet RecruitingNA

Application of the Health Action Process Approach Model Program to Patients With Heart Attacks

NCT06951958 · Heart Attack Patients

CV Wizard: Does a Clinical Decision Support Tool Improve CVD Risk Factor Control in Safety Net Clinics?

NCT03001713 · Heart Attack, Stroke, and more

Stress Management and Resiliency Training Following Acute Myocardial Infarction

NCT05415735 · Heart Attack, Cardiovascular Diseases

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: October 8, 2024Terms

Trial snapshot

StatusRECRUITING

PhasePHASE2

Enrollment81

Start dateAug 2022

Last updatedOct 8, 2024

Condition

Heart Attack Enlarged Heart

Locations shown

Minneapolis Heart Institute Foundation

Minneapolis, Minnesota

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 8, 2024Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions